Monitor for additional selling in the next 30 days and review upcoming Form 4s to determine if this is part of a broader trend. The small dollar size and timing with routine grants suggest limited significance, but continued selling could signal weakening confidence.
Price Chart
Executive Summary
Multiple executives at Esperion Therapeutics, including the CEO, CFO, and Chief Legal Officer, sold shares in the open market totaling approximately $102,352 over the past week. These sales coincided with large non-cash stock award grants to the same insiders, a routine compensation event, suggesting the sales may be part of pre-arranged 10b5-1 plans or personal liquidity management rather than a signal of fundamental concerns.
Key Financial Metrics
Key Facts
- CEO Sheldon Koenig sold $69,547 worth of shares, representing the largest individual sale in the cluster.
- CFO Benjamin Halladay and Chief Legal Officer Benjamin Looker sold $17,377 and $15,429 worth of shares, respectively.
- All three executives received substantial non-cash stock awards on March 13, totaling over 1.8 million shares collectively, which is consistent with annual equity compensation practices.
- Total open-market sales in the cluster amount to $102,352, representing just 0.015% of the company's $696M market cap — well below the 0.1% threshold for materiality.
- No insider purchases were reported; all transactions were either sales or non-cash grants.
Financial Impact
$102,352 in open-market sales by executives, offset by $0 in economic value from stock awards (non-cash).
Risk Factors
- Perception risk: Concentrated selling by top executives, even if planned, may be interpreted negatively by the market.
- Dilution: The large stock awards (over 1.8M shares) will increase share count, potentially pressuring per-share metrics if not offset by growth.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (9 trades, 7d window) | cluster-ESPR-1773864824503 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | Court Ruling | — | awaiting T+5 | — | — |
Aug 13, 2026 7w ago | Institutional Cluster | — | awaiting T+5 | — | — |
Jul 23, 2026 10w ago | 15-12G | — | awaiting T+5 | — | — |
Jul 16, 2026 11w ago | EFFECT | $3.18 awaiting T+5 | awaiting T+5 | — | — |
Jul 16, 2026 11w ago | EFFECT | $3.18 awaiting T+5 | awaiting T+5 | — | — |
Jul 13, 2026 11w ago | 25-NSE | $3.19 awaiting T+5 | awaiting T+5 | — | — |
Jul 13, 2026 11w ago | 8-K | $3.19 awaiting T+5 | awaiting T+5 | — | — |
Jun 16, 2026 15w ago | DEFA14A | $3.17 $3.15 | ▼ −0.63% | ▲ +0.41% | — |
Jun 11, 2026 16w ago | Institutional Cluster | $3.15 $3.17 | ▲ +0.63% | ▲ +0.20% | — |
Jun 9, 2026 16w ago | 8-K | $3.14 $3.16 | ▲ +0.64% | ▼ −2.80% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access